HD-OPM Archive
Topics › Inflammation & CRP

ZEUS: ziltivekimab cut hsCRP and IL-6 but did not reduce cardiovascular events

Louis Nervegna · Aug 01, 2026 · ♥ 10 reactions · 1 comments · original Facebook post
Inflammation & CRPHeart attack, stroke & procedures
AI summary & key facts

In the ZEUS trial, ziltivekimab reduced hsCRP and IL-6 as intended but heart attacks, strokes and CV deaths matched placebo, with more serious infections. Louis argues IL-6 is a marker of broad inflammation, which is why diet and colchicine work.

IL-6 was a logical target to test. It did seem promising.

But the IL-6 story for CVD is now looking a lot like HDL. It seems to be a marker; not a direct cause.

What is it a marker for?

I would argue: A more general pattern of inflammation in arteries and elsewhere.

Inflammation is much more complicated than just IL-6 alone.

The overall inflammatory pattern is what really matters. That’s what is likely causal in CVD. Not this one specific cytokine.

Interventions like diet and colchicine address this whole inflammatory pattern, not just IL-6 by itself. That’s probably why they work, while just inhibiting IL-6 fails.

#zeusHD #il6HD #hscrpHD #inflammationHD #ziltivekimabHD

Research cited

Does lowering an inflammation marker improve outcomes in atherosclerotic disease? In the ZEUS trial, ziltivekimab dropped hsCRP and IL-6 exactly as designed, and heart attacks, strokes and cardiovascular deaths came out identical to placebo, with more serious infections in the treatment arm.

Human systems like atherosclerosis and inflammation are complex, which is why trials that measure hard outcomes matter. Perhaps in these patients whose LDL-C was already low there was not as much room left to see a benefit.

No photo description available.
← newer: Vitamin-only advocate Andrew Saul died of congestive heart folder: Vigorous exercise is 4-10x more potent than moderate, and la →